Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis
Lancet
.
2023 Nov 18;402(10415):1833-1834.
doi: 10.1016/S0140-6736(23)01619-7.
Authors
Shivali Devjani
1
,
Priya V Engel
2
,
Sogol S Javadi
3
,
Brandon Smith
4
,
Jashin J Wu
5
Affiliations
1
SUNY Downstate College of Medicine, New York, NY, USA.
2
California University of Science and Medicine, Colton, CA, USA.
3
David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
4
Drexel University College of Medicine, Drexel University, Philadelphia, PA, USA.
5
Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Electronic address: jashinwu@gmail.com.
PMID:
37980089
DOI:
10.1016/S0140-6736(23)01619-7
No abstract available
Publication types
Letter
Comment
MeSH terms
Dermatitis, Atopic* / drug therapy
Double-Blind Method
Humans
Severity of Illness Index
Treatment Outcome